86 related articles for article (PubMed ID: 24806972)
1. Activation of endogenous type I IFN signaling contributes to persistent HCV infection.
Li Y; Li S; Duan X; Liu B; Yang C; Zeng P; McGilvray I; Chen L
Rev Med Virol; 2014 Sep; 24(5):332-42. PubMed ID: 24806972
[TBL] [Abstract][Full Text] [Related]
2. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.
Mukherjee A; Di Bisceglie AM; Ray RB
J Virol; 2015 Mar; 89(6):3356-65. PubMed ID: 25589644
[TBL] [Abstract][Full Text] [Related]
4. Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes.
Friborg J; Ross-Macdonald P; Cao J; Willard R; Lin B; Eggers B; McPhee F
PLoS One; 2015; 10(3):e0121734. PubMed ID: 25826356
[TBL] [Abstract][Full Text] [Related]
5. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment.
Chen L; Sun J; Meng L; Heathcote J; Edwards AM; McGilvray ID
J Gen Virol; 2010 Feb; 91(Pt 2):382-8. PubMed ID: 19846672
[TBL] [Abstract][Full Text] [Related]
6. HCV infection selectively impairs type I but not type III IFN signaling.
Chandra PK; Bao L; Song K; Aboulnasr FM; Baker DP; Shores N; Wimley WC; Liu S; Hagedorn CH; Fuchs SY; Wu T; Balart LA; Dash S
Am J Pathol; 2014 Jan; 184(1):214-29. PubMed ID: 24215913
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
[TBL] [Abstract][Full Text] [Related]
8. Innate immunity and HCV.
Heim MH
J Hepatol; 2013 Mar; 58(3):564-74. PubMed ID: 23063572
[TBL] [Abstract][Full Text] [Related]
9. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.
Metz P; Dazert E; Ruggieri A; Mazur J; Kaderali L; Kaul A; Zeuge U; Windisch MP; Trippler M; Lohmann V; Binder M; Frese M; Bartenschlager R
Hepatology; 2012 Dec; 56(6):2082-93. PubMed ID: 22711689
[TBL] [Abstract][Full Text] [Related]
10. HCV infection, IFN response and the coding and non-coding host cell genome.
Carnero E; Fortes P
Virus Res; 2016 Jan; 212():85-102. PubMed ID: 26454190
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection.
Bièche I; Asselah T; Laurendeau I; Vidaud D; Degot C; Paradis V; Bedossa P; Valla DC; Marcellin P; Vidaud M
Virology; 2005 Feb; 332(1):130-44. PubMed ID: 15661146
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus and microRNAs: miRed in a host of possibilities.
Singaravelu R; Russell RS; Tyrrell DL; Pezacki JP
Curr Opin Virol; 2014 Aug; 7():1-10. PubMed ID: 24721496
[TBL] [Abstract][Full Text] [Related]
13. Interaction of hepatitis C virus with the type I interferon system.
Weber F
World J Gastroenterol; 2007 Sep; 13(36):4818-23. PubMed ID: 17828812
[TBL] [Abstract][Full Text] [Related]
14. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection.
Shin EC; Seifert U; Kato T; Rice CM; Feinstone SM; Kloetzel PM; Rehermann B
J Clin Invest; 2006 Nov; 116(11):3006-14. PubMed ID: 17039255
[TBL] [Abstract][Full Text] [Related]
15. IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection.
Sung PS; Hong SH; Chung JH; Kim S; Park SH; Kim HM; Yoon SK; Shin EC
Sci Rep; 2017 Jun; 7(1):3821. PubMed ID: 28630501
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.
Crouchet E; Baumert TF; Schuster C
Expert Rev Proteomics; 2017 Jul; 14(7):593-606. PubMed ID: 28625086
[TBL] [Abstract][Full Text] [Related]
17. RNA-Seq-based analysis of differential gene expression associated with hepatitis C virus infection in a cell culture.
Hojka-Osinska A; Budzko L; Zmienko A; Rybarczyk A; Maillard P; Budkowska A; Figlerowicz M; Jackowiak P
Acta Biochim Pol; 2016; 63(4):789-798. PubMed ID: 27776194
[TBL] [Abstract][Full Text] [Related]
18. Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity.
Dagenais-Lussier X; Loucif H; Murira A; Laulhé X; Stäger S; Lamarre A; van Grevenynghe J
Viruses; 2017 Dec; 10(1):. PubMed ID: 29301196
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression.
Nishitsuji H; Ujino S; Yoshio S; Sugiyama M; Mizokami M; Kanto T; Shimotohno K
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10388-93. PubMed ID: 27582466
[TBL] [Abstract][Full Text] [Related]
20. Systems biology analyses to define host responses to HCV infection and therapy.
Ireton RC; Gale M
Curr Top Microbiol Immunol; 2013; 363():143-67. PubMed ID: 22903567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
